News

FDA allowing this technology to move forward to clinical investigation marks key milestone for regenerative hydrogel platform in treating complex colorectal conditions. Warrendale, PA – May 5, 2025 – ECM Therapeutics, Inc. (“ECMT”) has received U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for ECMT-100, a hydrogel derived from […]

PITTSBURGH–(BUSINESS WIRE)–ECM Therapeutics, a clinical stage regenerative medicine company pioneering the development of Extracellular Matrix-based therapeutics for the treatment of unmet medical needs, announces a collaboration with the Louis J. Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute led by José-Alain Sahel, MD, a distinguished professor and chair of the Department of Ophthalmology […]

ECM Therapeutics is proud to be the industry partner for this MTEC award to develop a temperature stable and ready-to-use ECM Hydrogel that initiates rapid and sustained hemostasis.

Macrophages are capable of extreme plasticity and their activation state has been strongly associated with solid tumor growth progression and regression. Although the macrophage response to extracellular matrix (ECM) isolated from normal tissue is reasonably well understood, there is a relative dearth of information regarding their response to ECM isolated from chronically inflamed tissues, pre-neoplastic tissues, and neoplastic tissues.

Intracerebral implantation of neural stem cells (NSCs) to treat stroke remains an inefficient process with <5% of injected cells being retained. To improve the retention and distribution of NSCs after a stroke, we investigated the utility of NSCs’ encapsulation in polyethylene glycol (PEG) microspheres.

Alarmins, sequestered self-molecules containing damage-associated molecular patterns, are released during tissue injury to drive innate immune cell proinflammatory responses. Whether endogenous negative regulators controlling early immune responses are also released at the site of injury is poorly understood.

Dr. Stephen Badylak, Dr. Blair Jobe, Dr. Prateek Sharma, and Dr. Bas Weusten invite you to a Cocktail Reception at Roy’s San Diego Waterfront.

In tissue engineering and regenerative medicine, a biomaterial provides mechanical support and biochemical signals to encourage cell attachment and modulate cell behaviour. Nature’s template for a biomaterial is the extracellular matrix (ECM). The ECM contains intrinsic biochemical and mechanical cues that regulate cell phenotype and function in development, in homeostasis and in response to injury.

ECM Therapeutics, Inc. ("ECMT") has obtained worldwide exclusive rights from the University of Pittsburgh for an extensive patent portfolio in certain fields of use based upon Extracellular Matrix ("ECM") technologies developed in the laboratory of Dr. Stephen Badylak at the McGowan Institute for Regenerative Medicine, and collaboratively with other Pitt investigators. The licensed technology includes ECM hydrogels, bioactive derivatives of ECM, and other forms of ECM, as well as methods required to deliver these materials to various anatomic sites such as the central nervous system, portions of the gastrointestinal tract, and musculoskeletal system, among others.